"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according ...

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext - ...

The revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...

Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive ...

Gaps in access to care persist for US patients with MS and impact HRQOL to a large extent. Improving access to care for patients with MS should be prioritized.

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

Five years after retiring from singing the Star Spangled Banner before every St. Louis Blues home game, Charles Glenn ...

A new study reveals how gender disparities cause therapeutic inertia in MS treatment for women, highlighting delays and ...